GH Guardant Health Inc

Price (delayed)

$24.18

Market cap

$2.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$6.41

Enterprise value

$3.69B

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health ...

Highlights
Guardant Health's revenue has increased by 20% YoY and by 4.4% from the previous quarter
The gross profit has grown by 17% YoY
Guardant Health's quick ratio has increased by 9% YoY but it has decreased by 3.7% from the previous quarter
GH's equity has shrunk by 91% YoY and by 64% QoQ
Guardant Health's net income has shrunk by 61% YoY and by 8% QoQ

Key stats

What are the main financial stats of GH
Market
Shares outstanding
102.66M
Market cap
$2.48B
Enterprise value
$3.69B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
41.16
Price to sales (P/S)
5.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.2
Earnings
Revenue
$449.54M
EBIT
-$650.87M
EBITDA
-$586.33M
Free cash flow
-$386.92M
Per share
EPS
-$6.41
Free cash flow per share
-$3.79
Book value per share
$0.59
Revenue per share
$4.4
TBVPS
$15.61
Balance sheet
Total assets
$1.61B
Total liabilities
$1.55B
Debt
$1.35B
Equity
$60.18M
Working capital
$998.37M
Liquidity
Debt to equity
22.39
Current ratio
6.17
Quick ratio
5.74
Net debt/EBITDA
-2.06
Margins
EBITDA margin
-130.4%
Gross margin
65.2%
Net margin
-145.6%
Operating margin
-121.1%
Efficiency
Return on assets
-35.9%
Return on equity
-242.7%
Return on invested capital
-24.1%
Return on capital employed
-45.9%
Return on sales
-144.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GH stock price

How has the Guardant Health stock price performed over time
Intraday
-1.23%
1 week
-13.46%
1 month
-16.27%
1 year
-59.42%
YTD
-11.1%
QTD
-11.1%

Financial performance

How have Guardant Health's revenue and profit performed over time
Revenue
$449.54M
Gross profit
$293.21M
Operating income
-$544.38M
Net income
-$654.59M
Gross margin
65.2%
Net margin
-145.6%
Guardant Health's net income has shrunk by 61% YoY and by 8% QoQ
The net margin has declined by 34% year-on-year and by 3.6% since the previous quarter
GH's operating income is down by 32% YoY and by 10% from the previous quarter
Guardant Health's revenue has increased by 20% YoY and by 4.4% from the previous quarter

Growth

What is Guardant Health's growth rate over time

Valuation

What is Guardant Health stock price valuation
P/E
N/A
P/B
41.16
P/S
5.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.2
The EPS has dropped by 60% year-on-year and by 8% since the previous quarter
The P/B is 174% more than the 5-year quarterly average of 15.0 and 57% more than the last 4 quarters average of 26.2
GH's equity has shrunk by 91% YoY and by 64% QoQ
The P/S is 82% below the 5-year quarterly average of 31.4 and 53% below the last 4 quarters average of 11.6
Guardant Health's revenue has increased by 20% YoY and by 4.4% from the previous quarter

Efficiency

How efficient is Guardant Health business performance
GH's ROA has dropped by 101% year-on-year and by 17% since the previous quarter
The ROE has plunged by 67% from the previous quarter
Guardant Health's ROIC has plunged by 61% YoY and by 11% from the previous quarter
The return on sales has declined by 34% year-on-year and by 3.5% since the previous quarter

Dividends

What is GH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GH.

Financial health

How did Guardant Health financials performed over time
Guardant Health's total assets is 3.9% more than its total liabilities
Guardant Health's total assets has decreased by 27% YoY and by 5% from the previous quarter
Guardant Health's quick ratio has increased by 9% YoY but it has decreased by 3.7% from the previous quarter
GH's debt to equity has surged by 176% since the previous quarter
GH's equity has shrunk by 91% YoY and by 64% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.